Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 4, 2008, Pages 816-822

  Jiménez Nácher, Inmaculada ^a   García, Benito ^b   Barreiro, Pablo ^a   Rodriguez Novoa, Sonia ^a   Morello, Judit ^a   González Lahoz, Juan ^a   De mendoza, Carmen ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

Author keywords

Antiretroviral therapy; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; NONHUMAN; PRESCRIPTION; SPAIN; TREND STUDY; VIREMIA; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PRESCRIPTIONS, DRUG; RNA, VIRAL; SPAIN; VIRAL LOAD;

EID: 52949129506     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn252     Document Type: Article

References (41)

1. Walensky R, Paltiel A, Losina E et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194: 11-9.
2. Fischl M, Richman D, Grieco M et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
3. Collier A, Coombs R, Fischl M et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786-93.
4. Sande M, Carpenter C, Cobbs G et al. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. J Am Med Assoc 1993; 270: 2583-9.
5. Carpenter C, Fischl M, Hammer S et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. J Am Med Assoc 1996; 276: 146-54.
6. Mouton Y, Alfandari S, Valette M et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. Acquir Immune Defic Syndr 1997; 11: F101-5.
7. Staszewski S, Morales-Ramirez J, Tashima K et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73.
8. Clumeck N, Goebel F, Rozenbaum W et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. Acquir Immune Defic Syndr 2001; 15: 1517-26.
9. Hsu A, Granneman G, Ritonavir Bertz R. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91.
10. Sackoff J, McFarland J, Shin S. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. J Acquir Immune Defic Syndr 2000; 23: 178-83.
11. Anonymous. Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002; 3: 28-36.
12. Jensen-Fangel S, Pedersen C, Larsen C et al. Trends in the use of highly active antiretroviral therapy in western Denmark 1996-2000. Scand J Infect Dis 2002; 34: 460-5.
13. Spira R, Marimoutou C, Binquet C et al. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidemiologie Clinique du SIDA on Aquitaine (GECSA). J Acquir Immune Defic Syndr 1998; 18: 358-64.
14. Mocroft A, Sabin C, Youle M et al. Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97. HIV Med 1999; 1: 32-9.
15. Kirk O, Mocroft A, Katzenstein T et al. Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. Acquir Immune Defic Syndr 1998; 12: 2031-9.
16. García-Benayas T, Blanco F, Alcolea A et al. Benefits in the lipid profile after substitution of abacavir for stavudine: A 48-week prospective study. AIDS Res Hum Retroviruses 2004; 20: 1289-92.
17. Soriano V, García-Gasco P, Vispo E et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial. J Antimicrob Chemother 2008; 61: 200-5.
18. Morello J, Garcia-Gascó P, Rodriguez-Novoa S et al. Association between tipranavir plasma levels and virological response in HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24: 389-91.
19. McConnell M, Byers R, Frederick T et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989-2001. J Acquir Immune Defic Syndr 2005; 38: 488-94.
20. Graham N. Studies of antiretroviral therapy in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1998; 17 Suppl 1: 9-12.
21. Furler M, Einarson T, Walmsley S et al. Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDS 2006; 20: 245-57.
22. Schiffer V, Deveau C, Meyer L et al. Recent changes in the management of primary HIV-1 infection: Results from the French PRIMO cohort. HIV Med 2004; 5: 326-33.
23. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995; 333 450-1.
24. Gross R, Bilker W, Friedman H et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. Acquir Immune Defic Syndr 2001; 15: 2109-17.
25. Hammer S, Squires K, Hughes M et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
26. Hogg R, O'Shaughnessy M, Gataric N et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
27. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
28. Chun T, Fauci A. Latent reservoirs of HIV: Obstacles to the eradication of virus. Proc Natl Acad Sci USA 1999; 96: 10958-61.
29. D'Arminio A, Sabin C, Phillips A et al. Cardio- and cerebrovascular events in HIV-infected persons. Acquir Immune Defic Syndr 2004; 18: 1811-7.
30. Ickovics J, Meade C. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 2002; 14: 309-18.
31. Deeks S. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002-11.
32. Cunningham W, Markson L, Andersen R et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr 2000; 25: 115-23.
33. Ghani A, Donnelly C, Anderson R. Patterns of antiretroviral use in the United States of America: Analysis of three observational databases. HIV Med 2003; 4: 24-32.
34. Carpenter C, Fischl M, Hammer S et al. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. J Am Med Assoc 1998; 280: 78-86.
35. Blanco F, Garcia-Benayas T, de la Cruz J et al. First-line therapy and mitochondrial damage: Different nucleosides, different findings. HIV Clin Trials 2003; 4: 11-9.
36. Petoumenos K. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: Results from the Australian HIV observational database. J Clin Virol 2003; 26 209-22.
37. de Mendoza C, Jiménez-Nacher I, Garrido C et al. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofavir. Clin Infect Dis 2008; 46: 1782-5.
38. Collier A, Coombs R, Schoenfeld D et al. Treatment of HIV infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334: 1011-7.
39. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Acquir Immune Defic Syndr 1998; 12: F51-8.
40. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
41. Sulkowski M, Thomas D, Mehta S et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35: 182-9.